Indoco Remedies gains on getting Certificate of EU GMP Compliance for sterile drug product manufacturing facility in Goa
Indoco Remedies is currently trading at Rs 317.25, up by 7.20 points or 2.32% from its previous closing of Rs 310.05 on the BSE.
The scrip opened at Rs 327.75 and has touched a high and low of Rs 327.75 and Rs 311.15 respectively. So far 2499 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 2 has touched a 52-week high of Rs 385.50 on 12-Sep-2024 and a 52-week low of Rs 190.00 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs 339.60 and Rs 308.60 respectively. The current market cap of the company is Rs 2901.66 crore.
The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 19.99% and 21.11% respectively.
Indoco Remedies has received Certificate for EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II located at L32, 33 and 34, Verna Industrial Estate, South Goa. The EU GMP certification issued by the European Health Authorities confirms that the site complies with the Good Manufacturing Practice requirements. The company remains fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
